期刊文献+

会诊一例变应性支气管肺曲霉病病人的体会

Personal experience in the consultation of one case of allergic bronchopulmonary aspergillosis
下载PDF
导出
摘要 目的:探讨临床药师参与临床会诊是否可使病人真正受益。方法:通过参与一例使用伏立康唑后出现严重药品不良反应(ADRs)的变应性支气管肺曲霉病病人的会诊,给医师提供个体化的药物治疗方案建议,为病人提供药学监护和用药教育服务等。结果:会诊意见优化了药物治疗方案,临床医师采纳了药师的建议,病人症状好转出院。结论:临床药师参与临床会诊,能提高药物治疗水平,保障病人用药的安全、有效、经济,使病人从个体化的药物治疗方案中获益。 Objective:To explore whether clinical pharmacists' involvement in medical consultation could really benefit patients.Methods:Through direct involvement in the medical consultation of one case of allergic bronchopulmonary aspergillosis with severe adverse drug reactions(ADRs),following medication of voriconazole,the clinical pharmacist recommended individualized treatment regimen to the clinical physician,provided the patient with pharmaceutical care and medication education,etc.Results:The consultation optimized the drug treatment regimen,and with the adaptation of the pharmacist's advice by the clinical physician,the patient's symptoms improved and was soon discharged from the hospital.Conclusion:Clinical pharmacists' direct involvement in medical consultation could improve drug treatment,ensure medication safety,enhance efficacy and save medical costs.As a consequence,the patient could benefit a great deal from individualized drug treatment regimen.
出处 《药学服务与研究》 CAS 2016年第1期37-40,共4页 Pharmaceutical Care and Research
关键词 临床药师 会诊 药物疗法 变应性支气管肺曲霉病 clinical pharmacist medical consultation drug therapy allergic bronchopulmonary aspergillosis
  • 相关文献

参考文献9

二级参考文献62

  • 1吴永佩,颜青,蒋学华,曾仁杰,甄健存.临床药师任职技术(准入)条件的探讨[J].中国药房,2005,16(7):484-487. 被引量:42
  • 2陈方淳,林梅.口腔念珠菌病患者口内菌株的检出和药敏性观察[J].华西口腔医学杂志,2007,25(1):37-41. 被引量:21
  • 3沈萍,张之烽.白色念珠菌对4种抗真菌药物的敏感性分析[J].临床输血与检验,2007,9(2):158-159. 被引量:5
  • 4邹玉娟 万迎春.伊曲康唑致急性药物性肝炎一例报告[J].临床肝胆病杂志,1998,14(2):124-125.
  • 5Andriole V T. Current and future antifungal therapy: new targets for antifungal therapy[J ]. Int J Antimierob Agents, 2000, 16: 317.
  • 6Denning D W. Echinocandin antiftmgal drugs[J ]. Lancet, 2003, 362: 1142.
  • 7Ashley E S D, Lewis R, Lewis J S, et al. Pharmacology of Systemic Antifungal Agents[]]. Clin Infect Dis, 2006, 43: S28.
  • 8Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaeonazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature[J]. Rev Iberoarn Micol, 2003, 20(4) : 121.
  • 9Theuretzbacher U. Pharmacokineties/pharmacodynamics of echinocandins[J]. Eur J Clin Microbiol Infect Dis, 2004, 23 (11): 805.
  • 10Hebert M F, Smith H E, Marbury T C, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction [J]. J Clin Pharmacol, 2005, 45(10): 1145.

共引文献252

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部